Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB +2.26%34 Net Cash per Share is $3.15 as of Jun. 2026, which is 47% above its 10-year median of 2.15. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 796 Biotechnology companies, Solid Biosciences ranks better than 59.05% on this metric.
Solid Biosciences (NAS:SLDB) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Solid Biosciences Net Cash per Share Related Terms
Solid Biosciences Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Solid Biosciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLDB vs MNPR, DSGN, CLYM: Net Cash per Share Comparison
For the Biotechnology subindustry, Solid Biosciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solid Biosciences Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solid Biosciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Solid Biosciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Solid Biosciences's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solid Biosciences (SLDB) has a Net Cash per Share of $3.15 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Solid Biosciences and its competitors. This is 47% above median its historical median of 2.15. Over the past decade, Solid Biosciences' Net Cash per Share has ranged from 0.49 to 14.43. According to the industry distribution chart, Solid Biosciences ranks #326 out of 796 companies in the Biotechnology industry, placing it in the top 41%.
Is Solid Biosciences' Net Cash per Share too high?
Solid Biosciences' current Net Cash per Share of $3.15 is 47% above median its 10-year median of 2.15. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 14.43. The Biotechnology industry median Net Cash per Share is 5.12. Solid Biosciences' value of $3.15 is 38.4% below this industry median. Based on the distribution chart, Solid Biosciences ranks #326 out of 796 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' Net Cash per Share compare to MNPR and DSGN?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #326 out of 796 companies for Net Cash per Share. This puts Solid Biosciences in the upper half of its industry. The industry median Net Cash per Share is 5.12. Solid Biosciences' value of $3.15 is 38.4% below this benchmark. Historically, Solid Biosciences' own Net Cash per Share has ranged from 0.49 to 14.43 over the past decade. While the company's 10-year median is 2.15 vs. the industry median of 5.12, Solid Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.12, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solid Biosciences's current Net Cash per Share of $3.15 is 38.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Solid Biosciences and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current Net Cash per Share is $3.15, which is 47% above median its own 10-year median of 2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current Net Cash per Share of $3.15. The current Net Cash per Share is $3.15, which is 47% above median its 10-year median of 2.15 and 38.4% below the Biotechnology industry median of 5.12. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current Net Cash per Share is $3.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
